Skip to main content

Prior asthma exacerbations predict future risk

Hospitalised patient_woman

The risk for moderate or severe asthma exacerbations is primarily predicted by the occurrence of prior corresponding exacerbations, shows research.


Overt, occult HBV infection remains a concern despite immunization


Despite a universal program to vaccinate newborns against hepatitis B virus infection, the prevalence of overt and occult infection among children in northwest China is a cause for concern, say researchers.


Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors

David Hyman

Preliminary findings for larotrectinib suggest that the agent may offer an effective tumor type-agnostic treatment for adults and children presenting with tropomyosin receptor kinase fusions.


Support for adding tofacitinib to methotrexate in patients with RA


Results of the ORAL Strategy trial suggest that tofacitinib given in combination with methotrexate, but not alone, is noninferior to adalimumab plus methotrexate for the treatment of patients with rheumatoid arthritis and an inadequate response to methotrexate.

Headlines from across medwireNews

27-06-2017 | Oncology | News | Article

Steady decline in serious comorbidities among pediatric cancer survivors

Research presented at the 2017 annual meeting of the American Society of Clinical Oncology shows childhood cancer survivors diagnosed in more recent years can expect to experience fewer serious chronic conditions than those diagnosed in earlier decades.

26-06-2017 | Oncology | News | Article

Aldoxorubicin has activity in advanced soft tissue sarcoma

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

23-06-2017 | Breast cancer | News | Article

Adjuvant capecitabine improves prognosis in high-risk breast cancer

Patients with residual invasive disease after standard neoadjuvant chemotherapy for HER2-negative breast cancer benefit from adjuvant treatment with capecitabine, CREATE-X trial data show.

23-06-2017 | Prostate cancer | News | Article

PAM50 classifier defines prostate cancer subtypes

Patients with prostate cancer can be classified into luminal- and basal-like subtypes using the well-known PAM50 algorithm, and the subtypes correlate with clinical outcome, researchers report.

23-06-2017 | Rheumatology | News | Article

Dose reduction of TNF inhibitors a ‘reasonable long-term approach’ for RA patients

The efficacy and safety profiles of disease activity-guided dose reduction of tumor necrosis factor inhibitors are maintained for up to 3 years in patients with rheumatoid arthritis, follow-up results of the DRESS study suggest.

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Beyond the news


medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Interested in paediatric endocrinology?

Visit our dedicated microsite for research news, interviews and in-depth analysis of paediatric endocrinology and growth disorders.


Highlights from the 1st conference of the European Academy of Neurology in Berlin, Germany.

Click through to read research news from the conference.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

image credits